{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-032004","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.278889+00:00","generated_at":"2026-05-23T21:10:04.709230+00:00","sec_items":["3.03"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quoin Pharma announces 1-for-20 reverse ADS split to regain Nasdaq compliance","bullets":["ADS ratio changed from 1:1 to 1:20 (one ADS now represents 20 ordinary shares) effective April 8, 2025.","Reverse split automatically converts every 20 existing ADSs into 1 new ADS; ordinary shares unchanged.","New CUSIP number for ADSs is 74907L409; ticker QNRX remains on Nasdaq Capital Market.","Objective is to increase ADS per-share price above $1.00 minimum bid to avoid delisting.","Company cannot guarantee that the ratio change will achieve or sustain Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-032004","json":"https://secwatch.observer/filing/0001104659-25-032004.json","markdown":"https://secwatch.observer/filing/0001104659-25-032004.md","text":"https://secwatch.observer/filing/0001104659-25-032004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925032004/0001104659-25-032004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925032004/tm2511401d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T21:10:04.709230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}